Treatment of TAMs with the small-molecule GLI 1 inhibitor GANT61, which could effectively inhibit the activity of the Hh signaling pathway in BC, restored M1 TAMs, as characterized by the upregulation of inducible nitric oxide synthase (iNOS) and TNF-α expression and the reduction in ARG-1 and CD206 expression, leading to CD8+ T cell trafficking back to the Br-TME where they exerted regulatory effects; these findings provide new ideas and directions for the clinical treatment of BC. The gene discussed is CD8A; the disease is breast cancer.